With actual and threatened lawsuits against U.S. industry costing consumers billions of dollars a year, CASE supports legal reforms that discourage excessive damage awards that saddle our economy and hurt U.S. competitiveness while bringing compensation awards more in-line with actual damages suffered. We oppose rules which permit plaintiffs’ attorneys to bundle and re-sell clients for class-action lawsuits. Common sense legal reforms that protect actual victims and discourage attorneys from seeking massive paydays on the backs of the public will help lower the $240 billion cost of America’s court system for civil suits. It will further reduce the costs consumers pay for goods and services and allow enterprise to continue to innovate and put more products on the market without fear of being sued out of business.
Search
Categories
- Aegis
- Agriculture
- Commerce
- Communications
- Consumer Safety
- Data Privacy
- Economy
- Education
- Energy
- Entertainment
- Environment
- Financial Services
- Fiscal Policy
- Healthcare
- Higher Ed on the Hill
- Housing
- Intellectual Property
- Kentucky
- Labor
- Legal
- Lifestyle
- Manufacturing
- Media
- Regulation
- Retail
- Robotexts
- Taxes
- TCPA
- Technology
- Trade
- Transportation
- Uncategorized
- Veterans
Archives
Contact Us
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/